Rula A. Hajj-Ali, MD

Rula A. Hajj-Ali, MD
Department of Rheumatic and Immunologic Disease, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation

Careen Lowder, MD, PhD
Cole Eye Institute, The Cleveland Clinic Foundation

Brian F. Mandell, MD, PhD
Vice-Chairman of Medicine for Educational Affairs; Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation; Editor-in-Chief, Cleveland Clinic Journal of Medicine

Address: Brian Mandell, MD, PhD, Vice-Chairman of Medicine for Educational Affairs, NA20, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mandelb@ccf.org

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Rula A. Hajj-Ali, MD
Department of Rheumatic and Immunologic Disease, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation

Careen Lowder, MD, PhD
Cole Eye Institute, The Cleveland Clinic Foundation

Brian F. Mandell, MD, PhD
Vice-Chairman of Medicine for Educational Affairs; Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation; Editor-in-Chief, Cleveland Clinic Journal of Medicine

Address: Brian Mandell, MD, PhD, Vice-Chairman of Medicine for Educational Affairs, NA20, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mandelb@ccf.org

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Rula A. Hajj-Ali, MD
Department of Rheumatic and Immunologic Disease, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation

Careen Lowder, MD, PhD
Cole Eye Institute, The Cleveland Clinic Foundation

Brian F. Mandell, MD, PhD
Vice-Chairman of Medicine for Educational Affairs; Department of Rheumatic and Immunologic Diseases, Center for Vasculitis Care and Research, The Cleveland Clinic Foundation; Editor-in-Chief, Cleveland Clinic Journal of Medicine

Address: Brian Mandell, MD, PhD, Vice-Chairman of Medicine for Educational Affairs, NA20, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail mandelb@ccf.org

This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.

Rula A. Hajj-Ali, MD
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic

Brian F. Mandell, MD, PhD
Education Program Director, Department of Rheumatic and Immunologic Diseases; Senior Associate Program Director, Internal Medicine Residency Program, Cleveland Clinic; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Department of Rheumatic and Immunologic Disease, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, mandelb@ccf.org

Rula A. Hajj-Ali, MD
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic

Brian F. Mandell, MD, PhD
Education Program Director, Department of Rheumatic and Immunologic Diseases; Senior Associate Program Director, Internal Medicine Residency Program, Cleveland Clinic; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Department of Rheumatic and Immunologic Disease, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, mandelb@ccf.org

Rula A. Hajj-Ali, MD
Department of Rheumatic and Immunologic Diseases, Cleveland Clinic

Brian F. Mandell, MD, PhD
Education Program Director, Department of Rheumatic and Immunologic Diseases; Senior Associate Program Director, Internal Medicine Residency Program, Cleveland Clinic; Deputy Editor, Cleveland Clinic Journal of Medicine

Address: Brian F. Mandell, MD, PhD, Department of Rheumatic and Immunologic Disease, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, mandelb@ccf.org